Michael Ross is a distinguished Principal Scientist at Immunitas Therapeutics, where he spearheads translational biomarker research for the lead molecule IMT-009, a monoclonal antibody designed to target the immune checkpoint receptor CD161 on T and NK cells. With a Ph.D. and a robust background in...
Michael Ross is a distinguished Principal Scientist at Immunitas Therapeutics, where he spearheads translational biomarker research for the lead molecule IMT-009, a monoclonal antibody designed to target the immune checkpoint receptor CD161 on T and NK cells. With a Ph.D. and a robust background in immuno-oncology, Michael leverages his extensive expertise in biomarker discovery and tumor immune profiling to drive innovative research strategies that bridge the gap between preclinical findings and clinical applications.
In his current role, Michael is instrumental in advancing the exploratory biomarker strategy, focusing on critical areas such as immunohistochemistry (IHC) for in vitro diagnostics (IVD), tumor biopsy evaluation, and comprehensive immunophenotyping. His work encompasses the evaluation of receptor occupancy and serum cytokines, as well as cutting-edge techniques like Nanostring and circulating tumor DNA (ctDNA) analysis. By collaborating closely with vendors and contract research organizations (CROs), he ensures the successful development of robust assays that meet the rigorous demands of Phase I and II clinical trials.
Michael’s proficiency in multi-color flow cytometry, cell culture, and molecular biology, combined with his adeptness in data analysis and statistical evaluation, positions him as a key contributor to the field of tumor immunology. His ability to communicate complex scientific concepts effectively further enhances his impact, allowing him to translate intricate research findings into actionable insights that drive therapeutic innovation. As he continues to explore the intricate dynamics of T cell and macrophage biology, Michael remains committed to advancing the understanding of immune responses in cancer, ultimately contributing to the development of more effective immunotherapeutic strategies.
